Benign Prostatic Hyperplasia - Pipeline Insight, 2024

This “Benign Prostatic Hyperplasia- Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Benign Prostatic Hyperplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Benign Prostatic Hyperplasia: Understanding

Benign Prostatic Hyperplasia: Overview

Benign Prostatic Hyperplasia (BPH) refers to the change in the size of the prostate and not the potential symptoms that it may cause, which are usually referred to as lower urinary tract symptoms (LUTS). LUTS may be primarily irritative, obstructive, or mixed. Men with BPH may be asymptomatic, respond to lifestyle changes, or require medical or surgical therapy; symptoms are more common as men age. The symptoms of Benign Prostatic Hyperplasia (BPH) include sensation of incomplete bladder emptying, straining to void, urinary hesitancy, weak urinary stream, dysuria, nocturia, urinary frequency, and urinary urgency. Assessment of medical history of the patient and physical examination, including a digital rectal examination (DRE) and urinalysis are done for diagnosis of BPH. Further investigations, such as uroflowmetry and measuring PVR volume, should help to confirm the presence of obstructive symptoms attributable to BPH. The two major classes of medications for BPH are alpha-adrenergic blockers and 5-alpha reductase inhibitors.

Benign Prostatic Hyperplasia- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Benign Prostatic Hyperplasia pipeline landscape is provided which includes the disease overview and Benign Prostatic Hyperplasia treatment guidelines. The assessment part of the report embraces, in depth Benign Prostatic Hyperplasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Benign Prostatic Hyperplasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Benign Prostatic Hyperplasia R&D. The therapies under development are focused on novel approaches to treat/improve Benign Prostatic Hyperplasia.

Benign Prostatic Hyperplasia Emerging Drugs Chapters

This segment of the Benign Prostatic Hyperplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Benign Prostatic Hyperplasia Emerging Drugs

Fexapotide: Nymox Pharmaceutical Fexapotide (NX-1207) is a pro-apoptotic injectable protein and is in development for the treatment of benign prostatic hyperplasia. In February 2023, Nymox Pharmaceutical Corporation announced that the Company's recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been validated by the Denmark authorities, and the formal review process has now started. The trademarked name for the new product is NYMOZARFEX (TM). The Marketing Authorization Application (MAA) was submitted at the beginning of December 2022. The Company will continue to provide further information, including other expected submissions, when the information becomesavailable.

AIV007: Ai Viva BioPharma AIV007 is a novel formulation using company's JEL Technology designed for prolonged drug release. AIV007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis, and it also modulates TGFß1 m RNA expression and TGFß1 levels to prevent and inhibit cell proliferation. AIV007 is currently in clinical studies for neovascular macular degeneration (nAMD) treatment and in preclinical studies for benign prostatic hyperplasia (BPH), andcertainsolidtumors.

Benign Prostatic Hyperplasia: Therapeutic Assessment

This segment of the report provides insights about the different Benign Prostatic Hyperplasia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Benign Prostatic Hyperplasia

There are approx. 80+ key companies which are developing the therapies for Benign Prostatic Hyperplasia. The companies which have their Benign Prostatic Hyperplasia drug candidates in the most advanced stage, i.e. preregistrtaion, Nymox Pharmaceutical.

Phases

This report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Benign Prostatic Hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Benign Prostatic Hyperplasia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Benign Prostatic Hyperplasia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Benign Prostatic Hyperplasia drugs.

Benign Prostatic Hyperplasia Report Insights

• Benign Prostatic Hyperplasia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Benign Prostatic Hyperplasia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Benign Prostatic Hyperplasia drugs?
• How many Benign Prostatic Hyperplasia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Benign Prostatic Hyperplasia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Benign Prostatic Hyperplasia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Benign Prostatic Hyperplasia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Nymox Pharmaceutical
• ASKA Pharmaceutical
• Otsuka Pharmaceutical
• Aiviva BioPharma
• KAEL-GemVax
• Dong-A ST/Mezzion

Key Products

• Fexapotide
• AKP009
• Tolvaptan
• AIV007
• Tertomotide
• Udenafil

This product will be delivered within 1-3 business days.